|Bid||2.9300 x 900|
|Ask||3.1900 x 1200|
|Day's range||2.7450 - 3.2400|
|52-week range||0.6070 - 3.7000|
|Beta (5Y monthly)||1.17|
|PE ratio (TTM)||N/A|
|Earnings date||07 Aug 2023 - 11 Aug 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||4.88|
Here is how Aquestive Therapeutics (AQST) and Corvus Pharmaceuticals (CRVS) have performed compared to their sector so far this year.
Shares of Corvus Pharma (CRVS) surge 69% this week after the company provided updates on its pipeline development in the first quarter of 2023 earnings release.
Corvus (CRVS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).